No press releases found.
Market Chameleon (Wed, 17-Dec 4:52 AM ET)
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Vyne Therapeutics trades on the NASDAQ stock market under the symbol VYNE.
As of March 31, 2026, VYNE stock price climbed to $0.60 with 142,742 million shares trading.
VYNE has a beta of 1.96, meaning it tends to be more sensitive to market movements. VYNE has a correlation of 0.04 to the broad based SPY ETF.
VYNE has a market cap of $19.89 million. This is considered a Sub-Micro Cap stock.
Last quarter Vyne Therapeutics reported $130,000 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-70,000 and exceeded earnings estimates by $.07.
In the last 3 years, VYNE traded as high as $8.73 and as low as $.28.
The top ETF exchange traded funds that VYNE belongs to (by Net Assets): VXF.
VYNE has underperformed the market in the last year with a return of -64.9%, while SPY returned +18.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VYNE shares. However, VYNE has outperformed the market in the last 3 month and 2 week periods, returning +6.1% and -1.9%, while SPY returned -5.1% and -2.5%, respectively. This indicates VYNE has been having a stronger performance recently.
VYNE support price is $.57 and resistance is $.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VYNE shares will trade within this expected range on the day.
